CAMBRIDGE, Mass., Sept. 6, 2022 (GLOBE NEWSWIRE) — hC Bioscience, Inc.a biotech developing first-in-class tRNA-based therapeutics targeting protein disruptions in genetically defined diseases and cancer, today announced that it has added Yosef Landesman, Ph.D., as leader to its executive and research and development teams has Scientific Officer and Gautam Goel, Ph.D., as Chief Data Science Officer.
“I am pleased to announce the continued expansion of our team as we build on our three pillars of expertise: translation and tRNA biology, computation and delivery,” said Leslie Williams, co-founder, president and chief executive officer of hC Bioscience. “The appointments of Drs. Landesman and Goel build on the addition of Dr. David Altreuter, who previously joined hC Bioscience as Chief Technology Officer. Under her leadership, we continue to expand our R&D team with members with expertise in tRNA biology, computational and biotechnology formulation. With the exceptional talent we have attracted, we believe we are well positioned to advance our complementary tRNA-based therapeutic platforms toward several important milestones.”
dr Landesman brings 20 years of drug discovery, development and regulatory experience in the biotechnology and pharmaceutical industries. Before joining hC Bioscience, Dr. Landesman is senior vice president of research and translational medicine at Karyopharm Therapeutics. From 2011 to 2022, his leadership was instrumental in advancing Karyopharm’s preclinical and clinical research, preclinical DMPK, translational medicine, bioinformatics and Expanded Access Program. Before Karyopharm, Dr. Landesman at Alnylam Pharmaceuticals, where he played a key role in establishing the RNAi Lead Development department and contributing to the development of ONPATTRO® (patiran). dr Landesman received his PhD in Molecular Genetics and Virology from the Weizmann Institute of Science and then completed his…
